After Thirty Years, We Still Cannot Understand Why Methylene Blue is not a Reference to Treat Vasoplegic Syndrome in Cardiac Surgery

After Thirty Years, We Still Cannot Understand Why Methylene Blue is not a Reference to Treat Vasoplegic Syndrome in Cardiac Surgery

Abstract Vasoplegic syndrome (VS) comprises a constellation of concurrent signs and symptoms: hypotension, high cardiac index, low systemic vascular resistance, low filling pressures, the tendency to occur diffuse bleeding, and sustained hypotension. All of these parameters may persist even despite the use of high doses of vasoconstrictor amines. VS arises from vasoplegic endothelial dysfunction with excessive release of nitric oxide by polymorphonuclear leukocytes mediated by the nitric oxide synthase’s inducible form and is associated with systemic inflammatory reaction and high morbimortality. The achievements regarding the treatment of VS with methylene blue (MB) are a valuable Brazilian contribution to cardiac surgery. The present text review was designed to deliver the accumulated knowledge in the past ten years of employing MB to treat VS after cardiac surgery. Considering that we have already published two papers describing acquired experiences and concepts after 15 and 20 years, now, as we achieve the 30-year mark, we compose a trilogy.

Saved in:
Bibliographic Details
Main Authors: Evora,Paulo Roberto B., Soares,Ricardo O. S., Bassetto,Solange, Auxiliadora-Martins,Maria, Luis-Silva,Fábio, Basile-Filho,Anibal
Format: Digital revista
Language:English
Published: Sociedade Brasileira de Cirurgia Cardiovascular 2021
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382021000300406
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0102-76382021000300406
record_format ojs
spelling oai:scielo:S0102-763820210003004062022-03-16After Thirty Years, We Still Cannot Understand Why Methylene Blue is not a Reference to Treat Vasoplegic Syndrome in Cardiac SurgeryEvora,Paulo Roberto B.Soares,Ricardo O. S.Bassetto,SolangeAuxiliadora-Martins,MariaLuis-Silva,FábioBasile-Filho,Anibal Vasoplegia Cardiac Surgical Procedures Methylene Blue Nitric Oxide Neutrophils Hypotension Abstract Vasoplegic syndrome (VS) comprises a constellation of concurrent signs and symptoms: hypotension, high cardiac index, low systemic vascular resistance, low filling pressures, the tendency to occur diffuse bleeding, and sustained hypotension. All of these parameters may persist even despite the use of high doses of vasoconstrictor amines. VS arises from vasoplegic endothelial dysfunction with excessive release of nitric oxide by polymorphonuclear leukocytes mediated by the nitric oxide synthase’s inducible form and is associated with systemic inflammatory reaction and high morbimortality. The achievements regarding the treatment of VS with methylene blue (MB) are a valuable Brazilian contribution to cardiac surgery. The present text review was designed to deliver the accumulated knowledge in the past ten years of employing MB to treat VS after cardiac surgery. Considering that we have already published two papers describing acquired experiences and concepts after 15 and 20 years, now, as we achieve the 30-year mark, we compose a trilogy.info:eu-repo/semantics/openAccessSociedade Brasileira de Cirurgia CardiovascularBrazilian Journal of Cardiovascular Surgery v.36 n.3 20212021-06-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382021000300406en10.21470/1678-9741-2021-0955
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Evora,Paulo Roberto B.
Soares,Ricardo O. S.
Bassetto,Solange
Auxiliadora-Martins,Maria
Luis-Silva,Fábio
Basile-Filho,Anibal
spellingShingle Evora,Paulo Roberto B.
Soares,Ricardo O. S.
Bassetto,Solange
Auxiliadora-Martins,Maria
Luis-Silva,Fábio
Basile-Filho,Anibal
After Thirty Years, We Still Cannot Understand Why Methylene Blue is not a Reference to Treat Vasoplegic Syndrome in Cardiac Surgery
author_facet Evora,Paulo Roberto B.
Soares,Ricardo O. S.
Bassetto,Solange
Auxiliadora-Martins,Maria
Luis-Silva,Fábio
Basile-Filho,Anibal
author_sort Evora,Paulo Roberto B.
title After Thirty Years, We Still Cannot Understand Why Methylene Blue is not a Reference to Treat Vasoplegic Syndrome in Cardiac Surgery
title_short After Thirty Years, We Still Cannot Understand Why Methylene Blue is not a Reference to Treat Vasoplegic Syndrome in Cardiac Surgery
title_full After Thirty Years, We Still Cannot Understand Why Methylene Blue is not a Reference to Treat Vasoplegic Syndrome in Cardiac Surgery
title_fullStr After Thirty Years, We Still Cannot Understand Why Methylene Blue is not a Reference to Treat Vasoplegic Syndrome in Cardiac Surgery
title_full_unstemmed After Thirty Years, We Still Cannot Understand Why Methylene Blue is not a Reference to Treat Vasoplegic Syndrome in Cardiac Surgery
title_sort after thirty years, we still cannot understand why methylene blue is not a reference to treat vasoplegic syndrome in cardiac surgery
description Abstract Vasoplegic syndrome (VS) comprises a constellation of concurrent signs and symptoms: hypotension, high cardiac index, low systemic vascular resistance, low filling pressures, the tendency to occur diffuse bleeding, and sustained hypotension. All of these parameters may persist even despite the use of high doses of vasoconstrictor amines. VS arises from vasoplegic endothelial dysfunction with excessive release of nitric oxide by polymorphonuclear leukocytes mediated by the nitric oxide synthase’s inducible form and is associated with systemic inflammatory reaction and high morbimortality. The achievements regarding the treatment of VS with methylene blue (MB) are a valuable Brazilian contribution to cardiac surgery. The present text review was designed to deliver the accumulated knowledge in the past ten years of employing MB to treat VS after cardiac surgery. Considering that we have already published two papers describing acquired experiences and concepts after 15 and 20 years, now, as we achieve the 30-year mark, we compose a trilogy.
publisher Sociedade Brasileira de Cirurgia Cardiovascular
publishDate 2021
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0102-76382021000300406
work_keys_str_mv AT evorapaulorobertob afterthirtyyearswestillcannotunderstandwhymethyleneblueisnotareferencetotreatvasoplegicsyndromeincardiacsurgery
AT soaresricardoos afterthirtyyearswestillcannotunderstandwhymethyleneblueisnotareferencetotreatvasoplegicsyndromeincardiacsurgery
AT bassettosolange afterthirtyyearswestillcannotunderstandwhymethyleneblueisnotareferencetotreatvasoplegicsyndromeincardiacsurgery
AT auxiliadoramartinsmaria afterthirtyyearswestillcannotunderstandwhymethyleneblueisnotareferencetotreatvasoplegicsyndromeincardiacsurgery
AT luissilvafabio afterthirtyyearswestillcannotunderstandwhymethyleneblueisnotareferencetotreatvasoplegicsyndromeincardiacsurgery
AT basilefilhoanibal afterthirtyyearswestillcannotunderstandwhymethyleneblueisnotareferencetotreatvasoplegicsyndromeincardiacsurgery
_version_ 1756429613218660352

Similar Items